Moleculin Biotech, Inc. (MBRX) stock
Close on Nov 12, 2026Market cap $156.99MP/E –Yield –
Moleculin Biotech, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$22.74M. At the latest close the market valued the company at $156.99M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $156.99M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 13.55
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$30.33M
- EPS, diluted
- -$15.01
- Free cash flow
- -$22.74M
- Book value per share
- $2.04
- Diluted shares
- 6M
Trading
- Previous close
- $8.10
- Open
- $8.77
- Day's range
- $7.90 – $8.90
- Volume
- 42,177
- Average volume (20 days)
- 46,415
- Beta (5 years)
- 1.17
- 52-week range
- $3.23 – $253.05
- RSI (14 days)
- 45.1
- Volatility (1 year)
- 136.8%
- Relative volume
- 0.75×
- WACC
- 10.8%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MBRX | S&P 500 | Difference | MBRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.6% | -2.7% | +0.1 pts | ||
| 3 months | -22.8% | -1.7% | −21.1 pts | ||
| Year to date | -87.8% | +11.9% | −99.7 pts | ||
| 1 year | -96.7% | +12.0% | −108.7 pts | ||
| 3 years | -99.8% | +78.2% | −178.0 pts | -87.4% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -78.7% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -61.9% | +15.1% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Moleculin Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- News
- Update
About Moleculin Biotech
Pharmaceutical Preparations
Moleculin Biotech is a late-stage pharmaceutical development company focused on creating treatments for hard-to-treat oncology indications and viruses. The company's lead drug candidate is Annamycin, a next-generation anthracycline designed to avoid cardiotoxicity and bypass multidrug resistance mechanisms. Its clinical pipeline also includes the WP1066 program targeting glioblastoma and other brain tumors, as well as the WP1122 portfolio of glycolysis inhibitors. Core clinical candidates serve patient populations with acute myeloid leukemia, soft tissue sarcoma lung metastases, and pediatric brain cancers.
Company profile, executives and historyMoleculin Biotech stock: common questions
What is Moleculin Biotech's stock price?
MBRX closed at $8.06 on Nov 12, 2026, down 0.49% on the day. Over the past 52 weeks it traded between $3.23 and $253.05.
What is Moleculin Biotech's market cap?
Moleculin Biotech was worth $156.99M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MBRX's P/E ratio?
Moleculin Biotech lost money over the twelve months to Jun 30, 2026 (diluted EPS -$15.01), so it has no meaningful P/E ratio.
How much revenue does Moleculin Biotech make?
Moleculin Biotech reported revenue of $0 for the twelve months to Jun 30, 2026.
Does Moleculin Biotech pay a dividend?
No. Moleculin Biotech has not paid a cash dividend over the last twelve months.
How has MBRX stock performed over the past year?
Including dividends, MBRX returned -96.7% over the past year, against +12.0% for the S&P 500.
How many MBRX shares are sold short?
0M shares were sold short at the latest FINRA report, 0.35% of the float, or 1.0 days of average trading volume.
Who are Moleculin Biotech's competitors?
Companies most similar to Moleculin Biotech by business, industry and size include SLS, PYXS, CLRB, KZIA, RNAZ.
See a number that looks wrong?